In Vivo Model Development for Hyperparathyroidism

Ace Therapeutics offers a comprehensive in vivo animal model development service tailored for hyperparathyroidism research. Leveraging a diverse portfolio of validated rat models, we enable our partners to evaluate the efficacy and safety of novel therapeutics targeting hyperparathyroidism and its underlying mechanisms. Our service encompasses model selection, development, and in-depth analysis, providing robust translational data to accelerate your preclinical programs.

Hyperparathyroidism is a complex endocrine disorder characterized by excessive secretion of parathyroid hormone (PTH), frequently associated with chronic kidney disease and disturbances in calcium-phosphate metabolism. Animal models are indispensable in elucidating disease mechanisms and evaluating new therapeutic interventions. At Ace Therapeutics, we primarily utilize Rattus norvegicus (Sprague Dawley rats), a species and strain widely recognized for their physiological similarity to human mineral metabolism and responsiveness to nephrectomy, dietary, and chemical manipulations. Our models accurately recapitulate the pathophysiological features of human hyperparathyroidism, ensuring high translational relevance for preclinical studies.

Surgical Nephrectomy Models

This model type involves partial (2/3 or 5/6) or total nephrectomy procedures in Sprague Dawley rats to induce renal insufficiency, a primary driver of secondary hyperparathyroidism. The methodology includes precise surgical removal of kidney tissue, sometimes combined with dietary modifications. Key advantages include reproducibility, well-established disease progression, and close mimicry of human chronic kidney disease-related hyperparathyroidism. These models are ideal for studying disease pathogenesis, evaluating pharmacological interventions, and investigating renal-bone axis interactions.

Dietary Modification Models

Dietary models use controlled administration of high-phosphate and/or low-calcium diets, often following nephrectomy, to exacerbate disturbances in mineral metabolism and stimulate parathyroid hormone secretion. This approach allows for fine-tuning of disease severity and rapid onset of hyperparathyroidism features. Advantages include flexibility in experimental design and the ability to model nutritional and environmental influences on disease. These models are particularly useful for studying the impact of diet on disease progression and for screening compounds targeting phosphate or calcium homeostasis.

Chemically-Induced Models

Chemically-induced models employ agents such as adenine to cause renal dysfunction or parathyroid hormone-related peptides to directly stimulate or ablate parathyroid function. For example, adenine administration leads to tubulointerstitial nephropathy and secondary hyperparathyroidism, while parathyroid hormone-related protein (1-34) can induce hyperparathyroid states in thyroparathyroidectomized rats. The main advantages are rapid and controlled disease induction and the ability to dissect specific molecular pathways. These models are valuable for mechanistic studies and for testing targeted therapeutics.

Ace Therapeutics delivers an end-to-end solution for in vivo hyperparathyroidism model development, encompassing model selection, surgical or chemical induction, dietary management, and comprehensive phenotypic characterization. Key efficacy endpoints include serum and urinary measurements of parathyroid hormone (PTH), calcium, phosphate, creatinine, and urea; bone mineral density analysis; histopathological assessment of parathyroid glands and kidneys; and molecular profiling of relevant pathways. Our analytical capabilities feature ELISA, biochemical assays, imaging (micro-CT), and quantitative PCR. Rigorous quality control measures are implemented at every stage, including standardized protocols, animal welfare monitoring, and data validation, to ensure reproducibility and scientific integrity.

Partnering with Ace Therapeutics empowers your hyperparathyroidism research with scientifically robust, clinically relevant animal models and integrated analytical support. Our experienced team ensures transparent communication, tailored study design, and timely project delivery. Contact us today to discuss how our in vivo hyperparathyroidism model development service can accelerate your therapeutic discovery and development pipeline.